Astellas Pharma Inc (ALPMY) 14.6600 $ALPMY Tokai Pharma

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Astellas Pharma Inc (ALPMY) 14.6600 $ALPMY

Tokai Pharma initiates late-stage study of galeterone in prostate cancer
Seeking Alpha - at Seeking Alpha - Wed Jun 24, 9:54AM CDT

MDVN: 106.81 (-2.19), TKAI: 13.69 (+0.97), QGEN: 25.73 (+1.00)

Vical's Genital Herpes Vaccine Fails in Phase I/II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 23, 2:55PM CDT
Vical Incorporated (VICL) announced disappointing top-line data from a phase I/II study on its investigational genital herpes vaccine.
VICL: 0.70 (unch), GILD: 113.74 (+0.38), ACOR: 34.07 (+0.65)

Roche to Develop Diagnostic Test for Cardiovascular Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 09, 9:00AM CDT
Roche Holding Ag (RHHBY) announced that it has entered into an agreement to develop a companion diagnostic (CDx) test for DalCor Pharmaceuticals' dalcetrapib.
VRX: 232.32 (+8.93), GILD: 113.74 (+0.38)

Astellas Pharma completes enrollment in CMV vaccine trial
Seeking Alpha - at Seeking Alpha - Thu May 21, 8:59AM CDT

VICL: 0.70 (unch)

Astellas' Myrbetriq for Overactive Bladder Efficient as Add-On - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 18, 1:25PM CDT
Astellas Pharma Inc. (ALPMY) announced positive results from a phase IIIb study on Myrbetriq-VESIcare add-on therapy in incontinent overactive bladder patients.
ACT: 298.98 (-2.94), VRX: 232.32 (+8.93)

Chugai Pharma Appears To Own U.S., Japan And EU Patent Rights To Medivation's Xtandi
BioPat Research - at Seeking Alpha - Tue May 12, 10:59AM CDT

MDVN: 106.81 (-2.19), JNJ: 99.53 (+1.13)

Vical Q1 Loss Narrower than Expected, Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 11, 1:24PM CDT
Vical Incorporated (VICL) posted a narrower-than-expected loss of 4 cents per share in the first quarter of 2015 driven by a year-over-year surge in revenues.
VICL: 0.70 (unch), ILMN: 219.45 (+2.28), HSP: 89.15 (+0.02)

Medivation (MDVN) Misses on Q1 Earnings, Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Fri May 08, 2:00PM CDT
Medivation's (MDVN) first quarter results were disappointing with the company missing on both the top and the bottom-lines.
MDVN: 106.81 (-2.19), GILD: 113.74 (+0.38), OSIR: 19.31 (+0.65)

Astellas and Potenza Therapeutics team up in cancer R&D
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 8:54AM CDT


Roche Collaborates with Astellas Pharma for Tissue Diagnostics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 5:22PM CDT
Roche Holding Ag (RHHBY) announced that its member company, Ventana Medical Systems, Inc. has entered into a master collaboration agreement with Japan-based Astellas Pharma Inc. (ALPMY).
MNK: 122.44 (+2.18), VRX: 232.32 (+8.93)

Merck KGaA-Pfizer to Co-promote Xalkori for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 08, 10:30AM CDT
Merck KGaA (MKGAF) and Pfizer will have signed an agreement to co-promote Xalkori in the U.S., Canada, five countries in the EU, Japan, China and Turkey for lung cancer.
CYTK: 6.10 (+0.02), PFE: 34.36 (+0.50)

Astellas-Medivation's Xtandi Meets Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 3:26PM CDT
Astellas Pharma Inc. (ALPMY) and Medivation announced positive top-line results from the phase II STRIVE study comparing Xtandi to Casodex in CRPC patients.
CYTK: 6.10 (+0.02), MDVN: 106.81 (-2.19), LCI: 59.93 (+2.37)

Xtandi successful in second Phase 2 prostate cancer study
Seeking Alpha - at Seeking Alpha - Thu Apr 02, 7:56AM CDT

MDVN: 106.81 (-2.19)

Vical In-Licenses Antifungal Drug ASP2397 from Astellas - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 3:17PM CDT
Vical (VICL) expanded its infectious disease portfolio by acquiring Astellas' (ALPMY) antifungal candidate, ASP2397.
LCI: 59.93 (+2.37), VICL: 0.70 (unch), CBM: 45.61 (+1.91)

Medivation-Astellas' Xtandi Positive in Prostate Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 26, 2:20PM CDT
Medivation, Inc. (MDVN) and Astellas Pharma jointly announced new data from a randomized, double-blind phase II study (TERRAIN) on Xtandi.
CYTK: 6.10 (+0.02), MDVN: 106.81 (-2.19), AZN: 66.45 (+1.90)

Xtandi beats bicalutamide in Phase 2 CRPC trial
Seeking Alpha - at Seeking Alpha - Tue Mar 24, 8:28AM CDT

MDVN: 106.81 (-2.19)

Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 5:12PM CDT
Amgen (AMGN) submits regulatory application for its cholesterol-lowering candidate, Repatha, in Japan.
LCI: 59.93 (+2.37), CBM: 45.61 (+1.91), AMGN: 154.10 (+2.79)

Best One-Drug Wonder Stock for 2015
Brian Orelli, Keith Speights, and George Budwell, The Motley Fool - Motley Fool - Sun Mar 22, 6:01AM CDT
If a biotech wants to become the next drugmaker with multiple blockbusters on the market, it has to start at the bottom with a single drug. We asked our biotech experts for their top picks for companies with just a single drug on the market. Read...
MDVN: 106.81 (-2.19), OREX: 4.70 (+0.04), ISIS: 53.50 (+0.42)

Amgen JV submits regulatory application in Japan for cholesterol med
Seeking Alpha - at Seeking Alpha - Fri Mar 20, 8:59AM CDT

AMGN: 154.10 (+2.79)

United Therapeutics' High-Risk Cancer Drug Wins FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 11, 4:40PM CDT
United Therapeutics' (UTHR) cancer drug Unituxin gained FDA approval plus a priority review voucher for the treatment of pediatric patients suffering from high-risk neuroblastoma.
LCI: 59.93 (+2.37), UTHR: 171.57 (+3.88), SLXP: 172.96 (+0.15)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 63

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 234

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

Updated Category News Views 315

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Continue Reading
Manhattan Associates Faces Investigation by KSF Law Firm

Updated Category News Views 219

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Continue Reading
MV Transportation Celebrates Leadership Nomination for FTA

Updated Category News Views 174

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 113

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 223

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
LaserAway Expands to 244 Clinics Over 20 Years

Updated Category News Views 186

A Milestone in Aesthetic Dermatology Twenty years, folks. That's a long haul for most businesses, let alone one in the fickle field of aesthetic dermatology. LaserAway, the juggernaut in this arena, has just opened its 244th clinic at 6300 Kingery Hwy in Willowbrook, IL. Nothing to be sneezed at. Imagine running a business, let alone one that's been amping up aesthetic...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 170

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 166

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading

Top 5 Most Recently Viewed Articles

Hofseth BioCare ASA Secures Funding Through Private Placement

Updated Category News Views 216

Hofseth BioCare ASA Successfully Completes a Private Placement Hofseth BioCare ASA, often referred to as HBC, has recently completed a significant private placement aimed at enhancing its growth capital and strengthening its corporate balance sheet. This strategic move is set to fund the company's ongoing developments and initiatives effectively. The Details of the...

Continue Reading
Prosus N.V. Announces Limit for Tender Offer Notes

Updated Category News Views 78

The Brass Tacks of Prosus's Recent Move Today, Prosus N.V. put a definitive cap on its cash tender offer, inviting investors to sell back their notes due in 2027. What’s happening under this financial tablecloth? We’re diving into a U.S.$1,035,854,000 cap on the tendered notes—shaved down from their new senior notes total of U.S.$1,650,000,000. Decoding the Offer:...

Continue Reading
Growth Potential of the Asia Pacific Conference Room Solutions Market

Updated Category News Views 119

Understanding the Growth in the Asia Pacific Conference Room Solutions Market The Asia Pacific conference room solutions market is on a remarkable growth trajectory, with valuations surging from US$ 300.08 million in 2023 to a stunning US$ 1,922.25 million projected by 2032, at a compound annual growth rate (CAGR) of 23.79%. This surge can be attributed to several...

Continue Reading
BexBack Launches High-Leverage Trading with Exciting Bonuses

Updated Category News Views 176

Exciting New Trading Features from BexBack BexBack, a leading cryptocurrency exchange platform, is thrilled to reveal its latest trading enhancements, designed for traders eager to amplify their market position. These innovative features are now accessible to users across the globe, marking a significant step in meeting the soaring demand for high-leverage crypto trading....

Continue Reading
NexGen Health Achieves Milestone with Stellar Customer Reviews

Updated Category News Views 200

NexGen Health Celebrate Customer Satisfaction Milestone Leading Silicon Valley wellness clinic's exceptional patient reviews emphasize their commitment to cutting-edge IV therapy, personalized care, and innovative health solutions. NexGen Health, Silicon Valley's premiere wellness and anti-aging clinic, proudly announces a significant customer satisfaction milestone with...

Continue Reading